EUVIMEDEUVIMED entdecken
Crossref

Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™

Zobair M Younossi iD, Ming-Lung Yu iD, Yusuf Yilmaz, Khalid Aida Alswat, Maria Buti, Marlen Ivon Castellanos Fernandez, Georgios Papatheodoridis iD, Saeed S Hamid, Mohamed El-Kassas iD, Wah Kheong Chan, Ajay K Duseja, Stuart C Gordon und 14 weitere

Journal of Viral Hepatitis · 2023

DOI: 10.1111/jvh.13800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Zobair M Younossi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Center for Liver Diseases, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. Hauptthemen laut MEDLINE: Hepatitis B, Virus Diseases, Hepatitis B, Chronic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient‐reported outcome (PRO) profile of CHB patients from different regions of the world using the Global Liver Registry. The CHB patients seen in real‐world practices are being enrolled in the Global Liver Registry. Clinical and PRO (FACIT‐F, CLDQ, WPAI) data were collected and compared to baseline data from CHB controls from clinical trials. The study included 1818 HBV subjects (48 ± 13 years, 58% male, 14% advanced fibrosis, 7% cirrhosis) from 15 countries in 6/7 Global Burden of Disease super‐regions. The rates of advanced fibrosis varied (3–24%). The lowest PRO scores across multiple domains were in HBV subjects from the Middle East/North Africa (MENA), the highest – Southeast/East and South Asia. Subjects with advanced fibrosis had PRO impairment in 3 CLDQ domains, Activity of WPAI ( p < 0.05). HBV subjects with superimposed fatty liver had more PRO impairments. In multivariate analysis adjusted for location, predictors of PRO impairment in CHB included female sex, advanced fibrosis, and non‐hepatic comorbidities ( p < 0.05). In comparison to Global Liver Registry patients, 242 controls from clinical trials had better PRO scores (Abdominal, Emotional, and Systemic scores of CLDQ, all domains of WPAI) ( p < 0.05). In multivariate analysis with adjustment for location and clinicodemographic parameters, the associations of PROs with the enrollment setting (real‐life Global Liver Registry vs. clinical trials) were no longer significant (all p > 0.10). The clinico‐demographic portrait of CHB patients varies across regions of the world and enrollment settings. Advanced fibrosis and non‐hepatic comorbidities are independently associated with PRO impairment in CHB patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis BVirus DiseasesHepatitis B, ChronicHumansMaleFemaleAntiviral AgentsSofosbuvirHepatitis B virusSurveys and QuestionnairesDrug Therapy, CombinationPatient Reported Outcome MeasuresLiver Cirrhosis

Stichwörter der Autor:innen

emotional well-beingfatiguefatty liverphysical functioningviral hepatitiswork productivity

Substanzen

Antiviral AgentsSofosbuvir

Autor:innen und Institutionen

  • Center for Liver Diseases, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
  • Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA.
  • Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.
  • School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
  • Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Liver Research Unit, Institute of Gastroenterology, Marmara University, İstanbul, Turkey.

ORCID-Profile: Zobair M Younossi, Ming-Lung Yu, Georgios Papatheodoridis, Mohamed El-Kassas, Stuart K Roberts, Ashwani K Singal, Aijaz Ahmed

Zitieren

APA

Younossi, Z. M., Yu, M. L., Yilmaz, Y., Alswat, K. A., Buti, M., Fernandez, M. I. C., Papatheodoridis, G., Hamid, S. S., El-Kassas, M., Chan, W. K., Duseja, A. K., Gordon, S. C., Eguchi, Y., Isakov, V. A., Roberts, S. K., Fan, J. G., Singal, A. K., Romero-Gómez, M., Ahmed, A., …, & Alqahtani, S. (2023). Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13800

Vancouver

Younossi ZM, Yu ML, Yilmaz Y, Alswat KA, Buti M, Fernandez MIC, et al. Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13800

BibTeX
@article{Younossi2023,
  author = {Younossi, Zobair M and Yu, Ming-Lung and Yilmaz, Yusuf and Alswat, Khalid Aida and Buti, Maria and Fernandez, Marlen Ivon Castellanos and Papatheodoridis, Georgios and Hamid, Saeed S and El-Kassas, Mohamed and Chan, Wah Kheong and Duseja, Ajay K and Gordon, Stuart C and Eguchi, Yuichiro and Isakov, Vasily A and Roberts, Stuart K and Fan, Jian-Gao and Singal, Ashwani K and Romero-Gómez, Manuel and Ahmed, Aijaz and Ong, Janus and Lam, Brian P and Younossi, Issah and Nader, Fatema and Racila, Andrei and Stepanova, Maria and Alqahtani, Saleh},
  title = {Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™},
  journal = {Journal of Viral Hepatitis},
  year = {2023},
  doi = {10.1111/jvh.13800}
}
Kostenlos starten →